CFB
REGN icon

Cullen/Frost Bankers’s Regeneron Pharmaceuticals REGN Stock Holding History

Cullen/Frost Bankers’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$641K Sell
1,028
-49
-5% -$33.4K 0.01% 413
2026
Q1 		$832K Buy
1,077
+647
+150% +$495K 0.01% 357
2025
Q4 		$332K Sell
430
-89
-17% -$60.4K ﹤0.01% 484
2025
Q3 		$292K Sell
519
-5,904
-92% -$3.34M ﹤0.01% 477
2025
Q2 		$3.37M Sell
6,423
-445
-6% -$248K 0.04% 218
2025
Q1 		$4.36M Buy
6,868
+561
+9% +$386K 0.06% 205
2024
Q4 		$4.49M Buy
6,307
+5,838
+1,245% +$4.9M 0.06% 200
2024
Q3 		$493K Buy
469
+42
+10% +$46.7K 0.01% 389
2024
Q2 		$449K Buy
427
+101
+31% +$97.9K 0.01% 394
2024
Q1 		$314K Buy
326
+9
+3% +$8.56K ﹤0.01% 421
2023
Q4 		$278K Sell
317
-20
-6% -$16.5K ﹤0.01% 439
2023
Q3 		$277K Buy
337
+50
+17% +$39.3K ﹤0.01% 455
2023
Q2 		$206K Sell
287
-40
-12% -$30.8K ﹤0.01% 497
2023
Q1 		$269K Hold
327
– – ﹤0.01% 466
2022
Q4 		$236K Sell
327
-31
-9% -$22.9K ﹤0.01% 479
2022
Q3 		$247K Buy
358
+62
+21% +$39K 0.01% 472
2022
Q2 		$175K Sell
296
-4
-1% -$2.6K ﹤0.01% 519
2022
Q1 		$210K Hold
300
– – ﹤0.01% 520
2021
Q4 		$189K Buy
300
+4
+1% +$2.46K ﹤0.01% 543
2021
Q3 		$179K Buy
+296
New +$184K ﹤0.01% 541
2021
Q1 		– Sell
-150
Closed -$72K – 1129
2020
Q4 		$72K Sell
150
-117
-44% -$63.2K ﹤0.01% 633
2020
Q3 		$149K Buy
267
+17
+7% +$10.3K ﹤0.01% 504
2020
Q2 		$156K Buy
250
+150
+150% +$85.1K ﹤0.01% 477
2020
Q1 		$49K Hold
100
– – ﹤0.01% 515
2019
Q4 		$38K Hold
100
– – ﹤0.01% 649
2019
Q3 		$28K Hold
100
– – ﹤0.01% 672
2019
Q2 		$31K Hold
100
– – ﹤0.01% 637
2019
Q1 		$41K Buy
+100
New +$41.2K ﹤0.01% 589

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Cullen/Frost Bankers's REGN Position: Q2 2026 in Review

Cullen/Frost Bankers reduced its Regeneron Pharmaceuticals (REGN) stake by 4.5% in Q2 2026, selling an estimated $33.4K and leaving 1,028 shares worth $641K. The position accounts for 0.01% of the portfolio, ranked #413.

Cullen/Frost Bankers first reported a position in REGN in Q1 2019 and has held it in 28 quarters since. The position peaked at $4.49M in Q4 2024. 729 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Cullen/Frost Bankers held 1,028 shares of Regeneron Pharmaceuticals worth $641K as of Q2 2026.
  • Cullen/Frost Bankers sold 49 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $33.4K.
  • Regeneron Pharmaceuticals made up 0.01% of Cullen/Frost Bankers's portfolio in Q2 2026, its #413 holding.
  • Cullen/Frost Bankers first reported a position in Regeneron Pharmaceuticals in Q1 2019 and has held it in 28 quarters since.
  • Cullen/Frost Bankers's Regeneron Pharmaceuticals position peaked at $4.49M in Q4 2024.
  • 729 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Cullen/Frost Bankers's 13F filing for Q2 2026, filed 27 Jul 2026.